[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extramedullary-disease-in-multiple-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extramedullary-disease-in-multiple-myeloma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622370","phase-2-a-phase-2-study-of-radiotherapy-induced-immune-priming-to-enhance-elranatamab-elra-in-relapsed-refractory-multiple-myeloma-rrmm-with-extramedullary-disease-emd-and-paramedullary-disease-pmd-prime-emd-pmd-100622370",false,"NCT07382739","A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\"","Inclusion Criteria\n\n* RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:\n\n  1. Relapsed disease: progressive disease (PD) \\>60 days after cessation of prior therapy\n  2. Refractory disease: PD \\\u003C=60 days after cessation of prior therapy, \\\u003C25% reduction in paraprotein (monoclonal protein \\[M-protein\\] or serum free light chains \\[sFLC\\]) or measurements of EMD\u002FPMD\n* Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria\n* At least one locus of EMD or PMD present on imaging (either PET\u002FCT or magnetic resonance imaging \\[MRI\\]):\n* EMD: extramedullary plasmacytoma, not a contiguous extension from a bone lesion.\n* PMD: paraskeletal plasmacytoma, contiguous extension from a bone lesion At least one locus of EMD\u002FPMD that was not previously radiated and can be treated with radiation\n* Hematology (supportive care is allowed, including transfusions and granulocyte colony stimulating factor (G-CSF), if cytopenia is deemed secondary to myeloma disease burden):\n* Hemoglobin (Hgb) \\>=7g\u002FdL\n* Platelet\\>=50K\u002FuL\n* Absolute neutrophil count (ANC) \\>=0.75K\u002FuL\n* Chemistry:\n* Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \\\u003C=2.5 x upper\n* limit of normal (ULN)\n* Total bilirubin (TBili) \\\u003C=1.5ULN (except for a known history of Gilbert syndrome)\n* Creatinine clearance (CrCL) \\>=30mL\u002Fmin\u002F1.73m2\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) \\\u003C=2, unless ECOG PS due to pain\u002Fmorbidity secondary to underlying myeloma disease, with the potential of improved ECOG PS to \\\u003C=2.\n* All participants must be either\n* Not of childbearing potential, or\n* Practicing at least 1 highly effective method of contraception until 6 months after the last dose of study treatment.\n* Childbearing age female participantsmust have a negative serum pregnancy test at screening and must agree to further pregnancy tests during the study.\n\nExclusion Criteria\n\n1. Prior or concurrent exposure to any of the following in the specified time frame prior to the first dose of Elra treatment:\n\n   * Within 14 days or at least 5 half-lives, whichever is less, of any investigational treatment\n   * Within 7 days of IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies\n   * Within 12 weeks of autologous stem-cell therapy (ASCT) or 6 months of AlloSCT and has to be off immunosuppressive agents \\>=42 days without signs of graft versus host disease (GVHD)\n   * Within 2 weeks of major surgery\n   * Within 6 months of cerebrovascular accident (CVA) events\n2. Waldenstrom, POEMS, Amyloidosis, ongoing plasma cell leukemia (PCL)\n3. History of Human Immunodeficiency Virus (HIV)\n4. Active, uncontrolled HBV infection despite antiviral therapy.\n5. Uncontrolled cardiac, pulmonary, gastrointestinal (GI), hepatic, renal, central nervous system(CNS) diseases not due to myeloma, at the discretion of investigator, that are not a candidate for T cell engager (TCE) therapy\n6. Uncontrolled or recurrent infections\n7. Autoimmune disease requiring systemic treatment (except for low dose steroids, equivalent to 10mg\u002Fday or less of prednisone)\n8. Disabling psychiatric conditions, substance abuse (alcohol, or drug), dementia, altered mental status\n9. Any other active malignancies within 5 years of completing treatment (with the exception of hormonal therapies for breast or prostate cancer) and \\>minimal risk of recurrence\n10. Myelodysplastic syndromes (MDS)\n11. Any issues that may impair the ability of the participant to receive or tolerate the planned treatment, to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that would prevent, limit, or confound the protocol specified assessments.\n12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Elra or other agents used in study.\n13. History or possible non-compliance with recommended treatments","ALL",{"count":17,"type":18},34,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.",[24,25,26,27,28,29,30],"Phase 2","Radiotherapy-Induced Immune Priming","Elranatamab","Relapsed Refractory Multiple Myeloma (RRMM)","Extramedullary Disease in Multiple Myeloma","Paramedullary Disease","PMD","RECRUITING","2026-04-09",{"date":34,"type":35},"2026-04-14","ACTUAL",{"date":37,"type":35},"2026-03-31",{"date":39,"type":18},"2030-12-31",{"name":41,"class":42},"M.D. Anderson Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":19,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100564328","phase-2-mezigdomide-carfilzomib-and-dexamethasone-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-in-patients-with-extramedullary-disease-100564328","NCT06627751","Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease","Phase II Clinical Trial of Mezigdomide\u002FCarfilzomib\u002FDexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* RRMM patients with one or more prior lines of therapy with at least one ES or PS lesion that is accessible to a biopsy. Accessibility will be assessed by the MM tumor board\n* Measurable disease meeting at least one of the following:\n\n  * Serum M-protein ≥1 g\u002FdL\n  * Urine M-protein ≥200 mg\u002F24 h\n  * Serum FLC assay: involved FLC level ≥10 mg\u002FdL provided serum FLC ratio is abnormal\n  * Up to 10 patients without measurable disease can be enrolled but screening imaging and\u002For bone marrow biopsy have to confirm RRMM. Follow-up response assessment will be performed with imaging using RECIST 1.1 and Deauville Criteria and bone marrow biopsies\n* Absolute neutrophil count: ≥ 1 x 10\\^9\u002FL\n* Platelets: ≥ 75 x 10\\^9\u002FL\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]): ≤ 3 x ULN\n* Renal function: Estimated creatinine clearance ≥ 30 mL\u002Fmin (Cockroft-Gault)\n* Adequate cardiac pump function with a left ventricular ejection fraction of ≥ 40%\n* Women of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for at least 28 days after the last dose of mezigdomide or 6 months after the last dose of carfilzomib. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Male patients (non-vasectomized) must agree to use contraception during the treatment period and for at least 28 days after the last dose of mezigdomide or 3 months after the last dose of carfilzomib and refrain from donating sperm during this period\n* Participant must understand the investigational nature of this study and sign an independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participant has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide (including ≥ grade 3 rash during prior thalidomide, lenalidomide, or pomalidomide therapy), carfilzomib or dexamethasone, any cereblon E3 ligase modulators (CELMoD) agents, or the excipients contained in the formulations, or participant has any contraindications per local prescribing information\n* Administration of strong CYP3A modulators or proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) within 2 weeks of starting study intervention\n* Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis\n* Patient has evidence of mucosal or internal bleeding and\u002For is platelet transfusion refractory\n* Any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient or would adversely affect his\u002Fher participation in this study\n* Known active infection requiring parenteral or oral anti-infective treatment within the past 14 days\n* Participant has a history of prior malignancy other than MM, except if the participant has been free of disease for ≥ 3 years or the participant had 1 of the following noninvasive malignancies treated with curative intent without known recurrence:\n\n  * Basal or squamous cell carcinoma of the skin\n  * Carcinoma in situ of the cervix or breast\n  * Stage 1 bladder cancer\n  * Incidental histological findings of localized prostate cancer such as tumor stage 1a or 1b (T1a or T1b) using the tumor, nodes, and metastasis (TNM) classification of malignant tumors OR prostate cancer that has been treated with curative intent\n* Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration\n* Pregnant or breast-feeding females\n* Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation\n* Known active HIV or hepatitis B or C viral infection\n* Known history of HIV infection\n* Systemic amyloidosis or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \\[M-protein\\] and skin changes)\n* Prior peripheral stem cell transplant within 12 weeks of study enrollment\n* Radiotherapy within 14 days prior to cycle 1 day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy\n* Known intolerance to steroid therapy\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Carfilzomib-refractory in the most recent line of therapy\n* Prior treatment with mezigdomide\n* Contraindication against conscious sedation\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug","18 Years",{"count":53,"type":18},28,[21],"This phase II trial studies how well mezigdomide\u002Fcarfilzomib\u002Fdexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \\[EMD\\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed\u002Frefractory multiple myeloma (RRMM) with EMD.",[28,57,58],"Recurrent Multiple Myeloma","Refractory Multiple Myeloma","2026-01-09",{"date":61,"type":35},"2026-01-12",{"date":63,"type":35},"2025-05-01",{"date":65,"type":18},"2030-05-01",{"name":67,"class":42},"Roswell Park Cancer Institute",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":19,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100560089","phase-1-external-beam-radiation-therapy-in-combination-with-talquetamab-for-the-treatment-of-multiple-myeloma-patients-with-extramedullary-disease-100560089","NCT06572605","External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease","A Phase 1b\u002F2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedullary Disease","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Age: ≥ 18 years\n* Karnofsky performance status (KPS) ≥ 60%\n* Diagnosis of multiple myeloma with extramedullary disease (EMD). EMD is defined as soft-tissue plasmacytomas NOT arising from skeletal lesions (i.e., the EMD is not contiguous with any bone\u002Fbony lesion)\n* Measurable systemic disease defined as serum M-spike ≥ 0.5 g\u002Fdl, 24-hour urine M-spike ≥ 200 mg\u002F24 hours (hr), involved serum free light chain (FLC) ≥ 10 mg\u002Fdl with abnormal FLC ratio, and\u002For a non-target plasmacytoma ≥ 2 cm in a single diameter (NOTE: Non-target plasmacytoma must not be included in the EMD-EBRT field)\n* At least one site of EMD must have an indication for palliative radiation per the treating clinicians (e.g., including but not limited to pain, asymmetry, discomfort, threatening to vital structure, etc.)\n* Target EMD site must be encompassed by one radiation field per treating radiation oncologist\n* Subject must have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody\n* Fully recovered from the acute non-hematologic toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy\n* Prior antitumor therapy must have been completed prior to enrollment as follows:\n\n  * ≥ 2 weeks for prior external beam radiotherapy (XRT) to non-target site\n  * ≥ 21 days for cytotoxic chemotherapy (systemic or intrathecal)\n  * ≥ 28 days for prior adoptive cell therapy or T-cell redirecting therapies\n  * ≥ 4 weeks or 5 half-lives (whichever is shorter) for other myeloma therapies\n* Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3 (prior growth factor support is permitted but must be without support for 7 days for granulocyte colony-stimulating factor \\[G-CSF\\] or granulocyte-macrophage colony-stimulating factor \\[GM-CSF\\] and for 14 days for pegylated GCSF before the laboratory test)\n\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Platelets ≥ 50,000\u002Fmm\\^3\n\n  * NOTE: No transfusion support or thrombopoietin receptor agonist within 7 days before laboratory test\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Hemoglobin ≥ 8g\u002FdL\n\n  * NOTE: No transfusion support or erythropoietin use within 7 days before the laboratory test\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Total bilirubin ≤ 2.0 X upper limit of normal (ULN) (unless has congenital bilirubinemia such as Gilbert's disease, in which case ≤ 1.5 × ULN is required)\n\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Aspartate aminotransferase (AST) ≤ 2.5 x ULN\n\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Alanine aminotransferase (ALT) ≤ 2.5 x ULN\n\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Creatinine clearance of ≥ 30 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula\n\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n  * Two repeat tests are allowed. If the repeat test satisfies criteria, the participant may enroll provided all other criteria are met\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of talquetamab\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Prior irradiation to target EMD site or field\n* Prior GPRC5D therapy\n* Prior radiopharmaceutical therapy\n* Patients who have received previous radiation to \\> 25% of their bone marrow\n* Prior allogeneic hematopoietic cell transplantation within the past 6 months or prior autologous hematopoietic cell transplantation within the past 12 weeks\n* A maximum cumulative dose of corticosteroids of ≥ 140 mg of prednisone or equivalent within 14-day period before the first dose of study drug (does not include pre-treatment medications)\n* Major surgery within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study, or within 2 weeks after administration of the last dose of study treatment\n\n  * Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery. If there is a question whether a procedure is considered a major surgery, the investigator must consult with the appropriate representative at Janssen and resolve any issues before enrolling a participant in the study\n* Ongoing or active infection\n* Severe persistent asthma or severe chronic obstructive pulmonary disease (COPD)\n* Presence of the following cardiac conditions:\n\n  * New York Heart Association stage III or IV congestive heart failure\n  * Myocardial infarction or coronary artery bypass graft ≤ 6 months prior to randomization\n  * Uncontrolled cardiac arrhythmia or clinically significant electrocardiogram (ECG) abnormalities\n  * History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration\n  * History of severe non-ischemic cardiomyopathy\n* Any of the following:\n\n  * Hepatitis B infection (i.e., hepatitis B virus surface antigen \\[HBsAg\\] or hepatitis B virus \\[HBV\\]-deoxyribonucleic acid \\[DNA\\] positive). In the event the infection status is unclear, quantitative viral levels are necessary to determine the infection status\n  * Active hepatitis C infection as measured by positive hepatitis C virus \\[HCV\\]-ribonucleic acid \\[RNA\\] testing. Participants with a history of HCV antibody positivity must undergo HCV-RNA testing. If a participant with history of chronic hepatitis C infection (defined as both HCV antibody and HCV-RNA positive) completed antiviral therapy and has undetectable HCV-RNA for at least 12 weeks following the completion of therapy, the participant is eligible for the study\n* Plasma cell leukemia (\\> 20% circulating plasma cells and\u002For \\> 2.0 x 10\\^9\u002FL plasma cells) at the time of screening, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary amyloid light chain amyloidosis\n* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain MRI and lumbar cytology are required\n* Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Stroke or seizure within 6 months prior to enrollment\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* If HIV positive, any of the following:\n\n  * Detectable viral load at screening\n  * CD4+ T cell count ≤ 300\n  * AIDS-defining opportunistic infection within 6 months of screening\n  * Changes in highly active antiretroviral therapy (HAART) due to resistance\u002Fprogression that occurred within 3 months prior to screening\n  * Changes in HAART due to toxicity within 4 weeks prior to screening\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":76,"type":18},20,[78,21],"PHASE1","This phase I\u002FII trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with extramedullary disease. Extramedullary disease in multiple myeloma involves the infiltration of organs and soft tissues by malignant plasma cells and has proven difficult to treat. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink cancers. EBRT is a type of radiation therapy that delivers high-energy beams to the cancer from outside of the body. In this trial, the EBRT will be directed to a site of extramedullary disease. Talquetamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Combining EMD-directed EBRT with talquetamab may be safe, tolerable, and\u002For effective in treating multiple myeloma patients with extramedullary disease.",[28,81],"Multiple Myeloma","2025-09-15",{"date":84,"type":35},"2025-09-19",{"date":86,"type":35},"2025-08-29",{"date":88,"type":18},"2030-01-18",{"name":90,"class":42},"City of Hope Medical Center"]